|
|
|
|
|
Balsalazide
drug data and news
Balsalazide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Balsalazide | ||
| Brand Names/Synonyms | BALSALAZIDE; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazido [Spanish]; Balsalazidum [Latin]; Carbadox; Colazal | ||
| Indication | For the treatment of mildly to moderately active ulcerative colitis | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Balsalazide is a prodrug that is enzymatically cleaved in the colon to produce mesalamine (5-aminosalicylic acid), an anti inflammatory drug indicated for the treatment of mildly to moderately active ulcerative colitis. Balsalazide disodium is delivered intact to the colon where it is cleaved by bacterial azoreduction to release equimolar quantities of mesalamine, which is the therapeutically active portion of the molecule, and 4-aminobenzoyl-(beta)-alanine. | ||
| Mechanism Of Action | The mechanism of action of 5-aminosalicylic acid is unknown, but appears to be topical rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that 5-aminosalicylic acid diminishes inflammation by blocking production of arachidonic acid metabolites in the colon. | ||
| Balsalazide News (When available) |
Salix Pharmaceuticals Reports 4Q2005 and FY2005 Results; 2005 ... Feb 24, 2006 Shire plc: Strong 2005 Performance Supports Positive Outlook Feb 23, 2006 | ||
| Dosage Forms | Not Available | ||
| Drug_Category | Anti-ulcer Agents; ATC:A07EC04 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Balsalazide: No drug interaction studies have been conducted for COLAZAL ô, however the use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 5-[4-(2-carboxyethylcarbamoyl)phenyl]azo-2-hydroxy-benzoicacid | ||
| Chemical Formula | C17H15N3O6 | ||
| Molecular Weight | 357.318 g/mol | ||
| Smiles String | C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 2.417 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | half-life could not be determined | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Balsalazide.html http://www.rxlist.com/cgi/generic2/balsalazide.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00141 | ||
| CAS Registry Number | 80573-04-2 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:192139 | ||
| PharmGKB ID | PA448536 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |